A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression by Mahoney, K.M. et al.
Vol.:(0123456789) 
Cancer Immunology, Immunotherapy (2019) 68:421–432 
https://doi.org/10.1007/s00262-018-2282-1
ORIGINAL ARTICLE
A secreted PD-L1 splice variant that covalently dimerizes and mediates 
immunosuppression
Kathleen M. Mahoney1,2  · Sachet A. Shukla1,4  · Nikolaos Patsoukis2  · Apoorvi Chaudhri1  · 
Edward P. Browne5  · Arnon Arazi4 · Thomas M. Eisenhaure4  · William F. Pendergraft III5 · Ping Hua1 · 
Hung C. Pham1 · Xia Bu1 · Baogong Zhu1 · Nir Hacohen3,4  · Edward F. Fritsch1,4,6 · Vassiliki A. Boussiotis2  · 
Catherine J. Wu1,4  · Gordon J. Freeman1 
Received: 25 May 2018 / Accepted: 2 December 2018 / Published online: 18 December 2018 
© The Author(s) 2018
Abstract
Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also known as CD274 or B7-H1) or 
its receptor programmed cell death-1 (PD-1) has shown improved survival for patients with numerous types of cancers, not 
limited to lung cancer, melanoma, renal cell carcinoma, and Hodgkin lymphoma. PD-L1 is a co-inhibitory molecule whose 
expression on the surface of tumor cells is associated with worse prognosis in many tumors. Here we describe a splice vari-
ant (secPD-L1) that does not splice into the transmembrane domain, but instead produces a secreted form of PD-L1 that has 
a unique 18 amino acid tail containing a cysteine that allows it to homodimerize and more effectively inhibit lymphocyte 
function than monomeric soluble PD-L1. We show that recombinant secPD-L1 can dimerize and inhibit T-cell proliferation 
and IFN-gamma production in vitro. The secPD-L1 variant is expressed by malignant cells in vitro that also express high 
levels of full-length PD-L1. Transcriptomic analysis of gene expression across The Cancer Genome Atlas found the strongest 
association of secPD-L1 with full-length PD-L1, but also with subsets of immunologic genes, such as in myeloid-derived 
suppressor cells. Moreover, the splice variant is also expressed in normal tissues and within normal peripheral blood cells 
it is preferentially expressed in activated myeloid cells. This is the first report of a form of secreted PD-L1 that homodimer-
izes and is functionally active. SecPD-L1 may function as a paracrine negative immune regulator within the tumor, since 
secPD-L1 does not require a cell-to-cell interaction to mediate its inhibitory effect.
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Introduction
Targeting immune checkpoints, such as programmed cell 
death-1 (PD-1) and its ligand programmed death ligand-1 
(PD-L1, also known as CD274 or B7-H1) has revolution-
ized the treatment of patients with cancer. PD-L1 is a cell-
surface ligand of the PD-1 and B7-1 receptors on lympho-
cytes. PD-L1 is expressed on immune cells, such as resting 
T cells, B cells, dendritic cells, and macrophage, as well as 
nonhematologic cells, such as the placenta. The interaction 
between the ligand PD-L1 and its receptor PD-1 mediates 
lymphocyte dysfunction, and blocking this interaction can 
restore lymphocyte function [3]. PD-L1 expression by tumor 
cells is associated with worse prognosis for patients with 
many types of tumor, such as kidney cancer [4]. Patients 
with higher levels of soluble PD-L1 detected in peripheral 
blood have worse clinical outcomes in both solid and hema-
tologic malignancies, including kidney, lung, and hepatocel-
lular carcinoma, as well as myeloma and diffuse large B cell 
lymphoma [5–9]. Whether soluble PD-L1 in patients is a 
surrogate for expression of PD-L1 by the tumor, be it tumor 
cells or the infiltrating immune cells, or a measure of immu-
nosuppressive peripheral blood cells is not well established 
across tumor types. Whether the soluble PD-L1 can deliver 
a negative regulatory signal through PD-1 is debatable [10].
PD-L1 expression on tumor cells can be a result of viral 
activation [11], oncogene expression, genomic changes in 
the tumor, such as gene amplification or disruption of the 3′ 
untranslated region [12, 13]. PD-L1 expression can also be 
induced by IFN-γ, termed adaptive resistance [14]. PD-L1 
is a transmembrane protein, which contains 7 coding exons, 
including a secretory signal at the amino terminus, IgV and 
IgC domains, a transmembrane domain, a short cytoplasmic 
tail, and a long 3′ untranslated region (Fig. 1a left, b upper). 
A soluble form of PD-L1 can be produced by tumor cell 
lines that express PD-L1 in vitro and by activated monocyte-
derived dendritic cells that also express high levels of PD-L1 
[6, 15]. It has been reported that soluble PD-L1 retains its 
immunosuppressive function [6] and can be generated by 
cleavage from the surface of cells by matrix metallopro-
teases (Fig. 1a, middle [16]). High levels of soluble PD-L1 
in sera of patients with melanoma prior to immune check-
point therapy were associated with increased likelihood of 
progressive disease after treatment with CTLA-4 blocking 
antibodies [17]. Regulation of PD-L1 at genetic, epige-
netic, transcriptional, translational, and post-translational 
levels has been described [18, 19]. Few splice variants of 
PD-L1 have been described or functionally characterized. In 
adult T-cell leukemia/lymphoma, splice variants of PD-L1 
have been described that affect the last 2 exons of the gene, 
encoding the cytoplasmic domain and 3′ untranslated region, 
enhancing mRNA stability and resulting in higher levels of 
expression of PD-L1 on the cell surface [13]. Multiple splice 
variants of PD-L1 have been reported that do not include 
the transmembrane domain but include more downstream 
exons, and thus may produce soluble forms of PD-L1 [17]. 
While it has been reported that molecularly engineered 
high-affinity PD-L1 can inhibit lymphocyte activation, B7 
family proteins such as PD-L1 classically require multim-
eric binding to mediate signaling through their CD28 fam-
ily receptors [20]. Thus native monomeric soluble PD-L1 
would not be expected to functionally inhibit lymphocytes. 
Here we describe an alternative splice variant of PD-L1 that 
encodes a secreted form of PD-L1 (secPD-L1) with a unique 
cysteine-containing 18-amino acid domain which can dimer-
ize. secPD-L1 can inhibit lymphocyte function in vitro. We 
show that cells expressing high levels of the full-length 
PD-L1 protein also express this secreted variant in vitro 
including tumors in the TCGA and some normal tissues. 
This secreted variant of PD-L1 may be an additional means 
by which cells can regulate T-cell function in the tumor 
microenvironment without requiring cell–cell interaction.
Methods
Isolation of secPD-L1 cDNA Placenta RNA was purchased 
from Clontech Laboratories, Inc and was used to make the 
cDNA library [3]. A Rec-A-based system was used to clone 
PD-L1 cDNAs (Clone Capture kit) including full-length 
membrane and secreted isoforms by hybridization to plas-
mid cDNA libraries prepared from placenta mRNA [21, 22].
Cell lines All tumor cell lines were maintained as 
described previously [23].
PCR analysis of RNA expression in cell lines and acti-
vated dendritic cells RNA was isolated with RNAeasy Kit, 
reverse transcribed and PCR of full-length PD-L1 and the 
secreted variant of PD-L1 (secPD-L1) crossing exon–exon 
junctions was performed. To amplify the secPD-L1 mRNA 
qualitatively, PCR products after 30 cycles of amplification 
with O-3806 [crosses exon 3–4] (F1:ACT GTG AAA GTC 
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AAT GCC CC) and O-3816 [within the intron after exon 4] 
(R1: GCT AGG GGA CAG TGT TAG AC, product 354 bp) 
or O-3818 [more 3′ within the intron after exon 4] (R2: 
GGA TGA ATG GAG GTG AGG AA, product 465 bp) were 
analyzed; under the same conditions we amplified the full-
length PD-L1 mRNA with O-3808 [crosses exon 4–5 junc-
tion] (F2: ACA GCT GAA TTG GTC ATC CC) and O-3820 
(R3: CTT GGA GGC TCC TTG TTC AG, product 505 bp) 
or O-3822 (R4: AGG GAT TCT CAA CCC GTC TT, product 
550 bp) (Supplemental Fig. 2B upper, 2C). Quantitative 
PCR requires a shorter secPD-L1 PCR product for paral-
lel PCR efficiency, which could also result in amplifica-
tion of genomic DNA; thus RNA was treated with DNAse 
prior to cDNA production. TaqMan PD-L1 primers were 
used to detect mRNA expression of the transmembrane 
domain containing form of full-length PD-L1 or the unique 
3′ sequence of secPD-L1, respectively: full-length PD-L1 
(cat# Hs01125299_m1) and secPD-L1 (Cat# 4331348; ID: 
AI0IYL3) (schema in Supplemental Fig. 2B lower) and 18S 
control. The figure is representative of 3 or more Q-PCR 
experiments.
Expression quantification of the PD-L1 isoforms We 
first created a list of 36-mers tags derived from the secreted 
(secPD-L1) and the full-length membrane-bound (full-
length PD-L1) transcriptomic isoforms of PD-L1. In a given 
RNA-seq library, reads deriving from either of these two 
isoforms were identified based on perfect matches to any tag 
in the list. Identified reads were then aligned to the secPD-
L1 and full-length PD-L1 isoforms using a precise alignment 
method (Novoalign, http://www.novoc raft.com), we defined 
the following quantities:
nfull-length PD-L1 is the # reads mapping to the 804 bases 
uniquely found at the 3′end of the full-length PD-L1 iso-
form; nsecPD-L1 is the # reads mapping to the 208 bases 
uniquely found at the 3′end of the secPD-L1 isoform; N is 
the # reads in the RNA-seq library.
Normalized full-length and secPD-L1 counts were cal-
culated as:
The relative expression of full-length and secPD-L1 was 
calculated as:
Samples with normalized isoform counts above 0 





















was assigned to 1 of 4 classes: full-length+ sec+, full-
length + sec-, full-length− sec+, full-length− sec− based on 
the status of the secPD-L1 and full-length PD-L1 isoforms 
within the sample. The gradient of color is used to denote 
the expression level of the full-length PD-L1 in any tumor 
expressing full-length PD-L1 or expression level of secPD-
L1 in the secPD-L1 exclusive (yellow) tumor specimens.
Transcriptomic databases Expression levels of full-length 
PD-L1 and secPD-L1 were analyzed in publicly available 
tumor specimens from The Cancer Cell Line Encyclopedia 
(CCLE), The Cancer Genome Atlas (TCGA), normal tissue 
specimens prepared from autopsy [Genotype-Tissue Expres-
sion (GTEx) database], melanoma specimens from patients 
treated with ipilimumab or PD-1 therapy [24, 25]. The data 
used for the analyses described in this paper were obtained 
from the GTEx Portal dbGaP accession number phs000424.
v6.p1. Sorted peripheral blood cells were sequenced per 
protocol from normal healthy donors [University of North 
Carolina Internal Review Board (IRB) # 13-3774].
Recombinant secPD-L1 To confirm expression and secre-
tion of the secPD-L1 protein, we subcloned the cDNA into 
the pEF-Puro expression plasmid and transfected 300.19 
cells, a mouse pre-B cell line and assayed cell-free superna-
tants. Recombinant His-tagged secPD-L1 was produced in 
CHO cells and purified by its C-terminal His tag for func-
tional assays and verified to have endotoxin levels below 
2 EU/mg of protein. To assess multimerization of PD-L1, 
Western blot analysis of recombinant proteins following 
SDS–PAGE with and without beta-mercaptoethanol was 
performed on the PD-L1 extracellular domain (Met 1-Thr 
239) with a C-terminal hexahistidine tag, which will be 
referred to as ECD-PD-L1 (Sino Biological 10084-H08H), 
and the purified recombinant secPD-L1. The PD-L1 mono-
mer and multimers were detected with a murine monoclonal 
PD-L1 antibody that detects an epitope in the IgV domain of 
the extracellular domain of human PD-L1 (clone 368A.5A4, 
0.25 µg/ml) [23]. In-fusion-mediated site-directed mutagen-
esis was used to mutate cysteine 239 to serine to determine 
the role of cysteine 239 in multimerization of secPD-L1 
[26]. Expression of PD-L1 by cells transfected with vector, 
secPD-L1 or full-length PD-L1 was assayed by flow cytom-
etry with anti-human PD-L1 (clone 339.6A2).
Lymphocyte activation assays PBMCs were purified by 
Ficoll gradient and T cells were isolated with Miltenyi beads 
(PanT cell kit, Cat# #130-096-535) and activated by soluble 
anti-CD3 and anti-CD28 antibodies (Fitzgerald Industries) 
at 100 ng/ml each in the presence of recombinant secPD-
L1-His or the ECD-PD-L1 at increasing doses (5, 10, and 
20 µg/ml). To assess the effect of secPD-L1 and ECD-PD-L1 
on T-cell activation, supernatants were analyzed for IFN-γ 
production (Biolegend, Cat# 430102) at 48 h of stimulation. 
Proliferation was assessed by  [3H]-thymidine incorporation 
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for the last 16–18 h of 72-h cultures [27]. The figure is rep-
resentative of two lymphocyte activation experiments.
Results
A secreted splice variant of PD-L1 is expressed by human 
placenta PD-L1 is a glycosylated Type I membrane protein 
of the B7-family of immunomodulatory ligands. PD-L1 is 
highly expressed on some normal tissue such as the placenta, 
as well as on many hematologic cells. We cloned full-length 
(Fig. 1a, left; b, top) and alternatively spliced forms of the 
human PD-L1 cDNA from placental tissue by a hybridi-
zation method with RecA-coated biotinylated DNA probes 
[3, 21]. Sequencing of clones revealed an alternate splice 
variant, which we refer to as secPD-L1 (Fig. 1a, right, b, 
bottom), that contains the first 4 exons of PD-L1, including 
the secretory signal at the N terminus, IgV and IgC domains, 
which are shared with the full-length PD-L1. However, 
secPD-L1 does not splice into the fifth exon, which encodes 
the transmembrane domain, but reads into the fourth intron 
that results in a new stop codon, alternate 3′ untranslated 
region and polyadenylation site. Thus, the secPD-L1 splice 
variant produces an mRNA that contains a secretory signal 
at the 5′ end, lacks a transmembrane domain at its 3′ end 
and has 207 base pairs that differ from the 3′ end of the 
full-length PD-L1 mRNA (Supplemental Fig. 1a), and pre-
dicts a protein with a unique carboxyl terminal sequence: 
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Fig. 1  A splice variant of PD-L1 mRNA encodes a soluble form of 
PD-L1 that can covalently dimerize. a Protein schema of transmem-
brane PD-L1 (left) and a soluble PD-L1 cleaved from the cell surface 
(middle) and the dimeric secPD-L1 splice variant (right, C indicates 
a cysteine in the carboxyl-terminal domain). b Exons and introns of 
full-length PD-L1 (top) and secPD-L1 splice variant with unique 
cysteine-containing carboxyl-terminal domain (bottom; N-linked gly-
cosylation motif (NVS) underlined). c Western blot analysis of PD-L1 
in cell-free supernatants from 300.19 cells expressing either full-
length PD-L1 or secPD-L1 (open arrow). d Western blot analysis of 
recombinant extracellular domain of PD-L1 and secPD-L1, in reduc-
ing and non-reducing conditions (open arrow indicating monomeric 
PD-L1 and closed arrow indicating dimeric secPD-L1 protein)
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The secPD-L1 splice variant encodes a secreted protein 
and recombinant secPD-L1 dimerizes We cloned the secPD-
L1 cDNA into expression vectors and confirmed that this 
cDNA encodes a secreted protein by stably transfecting 
cells with the secreted splice variant of PD-L1 (secPD-L1), 
full-length PD-L1, or empty vector. Assaying supernatants 
from transfected cells by western blot analysis confirmed the 
secPD-L1 protein was secreted with an estimated size of 42 
KD (Fig. 1c). Flow cytometry of transfected cells showed 
little PD-L1 was expressed on cells transfected with secPD-
L1 compared to cells transfected with full-length PD-L1 
(Supplemental 1b). The secPD-L1 unique C-terminal 
domain contains a cysteine, which suggests that secPD-L1 
may homodimerize (Fig. 1b, bottom). Using a PD-L1 anti-
body that recognizes an epitope in the IgV domain, we per-
formed western blot analysis of recombinant secPD-L1 and 
compared it to recombinant extracellular domain of PD-L1 
under non-reducing and reducing conditions to determine 
whether the secPD-L1 variant migrated differently than a 
form of PD-L1 cleaved from the full-length membrane pro-
tein (Fig. 1d). In reducing conditions, both migrated at about 
40 KD; however, in non-reducing conditions, the recombi-
nant extracellular domain of PD-L1 remained monomeric, 
while the secPD-L1 had a molecular weight consistent with 
a dimeric structure with some larger multimers. Mutation of 
cysteine 239 to serine in the recombinant secPD-L1 largely 
abrogated multimerization of the isoform (Supplemental 
Fig. 1c).
SecPD-L1 is immunosuppressive in vitro  Soluble PD-L1 
has been reported to bind PD-1 and retain immunosuppres-
sive activity in vitro. If signaling is dependent on crosslink-
ing the PD-1 receptor, a monomeric cleaved form of PD-L1 
would not be expected to be functional. Functional assays 
performed with recombinant PD-L1-Fc fusion proteins 
allow for dimerization by the Fc portion of the recombinant 
protein [6]. Given that the secPD-L1 variant can naturally 
dimerize, we compared the functional activity of recombi-
nant secPD-L1 and a recombinant PD-L1 containing only 
the extracellular domain without the sec-specific carboxyl 
terminus and similarly purified with a His tag, rather than an 
Fc fusion, to determine whether secPD-L1 has immunosup-
pressive activity. We found that secPD-L1 at 10 µg/ml con-
centrations could inhibit T-cell proliferation and production 
of IFN-γ from T cells stimulated with CD3/CD28 coactiva-
tion, and was more inhibitory than the soluble extracellular 
domain of PD-L1 (Fig. 2a, b).
SecPD-L1 RNA is expressed in PD-L1-positive malignant 
cell lines We have developed monoclonal antibodies (mAb) 
to detect PD-L1 in flow cytometry, western blot, and immu-
nohistochemical analysis [22, 23, 28]. Within this set of 
tools, we have mAbs that recognize distinct domains within 
PD-L1 (IgV, IgC, cytoplasmic). While we have developed 
an ELISA assay to detect soluble PD-L1 [17], our attempts 
to produce high-affinity antibodies specific for the unique 18 
amino acids at the carboxyl terminus of secPD-L1 to distin-
guish whether soluble PD-L1 in patient sera is the secreted 
variant described here have not yet been successful. A chal-
lenge in developing an antibody specific for the secPD-L1 
variant may be due to the C-terminal region of secPD-L1 
having an N-linked glycosylation motif (NVS, underlined 
in Fig. 1b) that could block mAb access. However, since 
there is a distinct 3′ nucleotide sequence in the carboxyl 
terminus and 3′UTR that differ between the full-length and 
secPD-L1, we were able to measure mRNA expression of 
the secPD-L1 variant in a series of cell lines by RT-PCR. 
We have previously reported immunohistochemistry and 
western blot analysis with the 405.9A11 mAb, which rec-
ognizes an epitope in the cytoplasmic domain of full-length 
PD-L1, and corresponded with surface expression of PD-L1 
by flow cytometry and a membranous pattern of expression 
of PD-L1 on tumor cells [23]. We screened a series of cell 
lines with established positive or negative PD-L1 protein 
status by flow cytometry and western blot analysis, including 
lymphomas [HDLM-2(+) and OC1-LY1(−)] [12], renal cell 
carcinoma [Caki-2(+), UMRC6(−)] [23], and breast cancer 
cell lines [MDA231(+), SKBR3(+), and BT474(-)] [28] to 
determine whether the secPD-L1 variant mRNA expression 
was associated with expression of the full-length PD-L1 by 
RT-PCR analysis. PCR with exon–exon bridging primers 
established that cell lines expressing the full-length PD-L1 
(HDLM2, Caki-2, MDA231, and SKBR3) also expressed 
secPD-L1 mRNA (Supplemental Fig. 1b, c). The exon–exon 
bridging PCR product for the secPD-L1-specific product 
was > 400 bp given the shared exon 4 sequence between 
the full-length and secPD-L1 cDNA (Supplemental Fig. 1b, 
c). To compare relative amounts of full-length and secPD-
L1 by quantitative real-time PCR, we used a standard set 
of TaqMan primers specific for the cDNA encoding the 
transmembrane domain or custom TaqMan primers specific 
for the unique intronic sequence encoded in secPD-L1 on 
DNAse-treated RNA samples (Fig. 2c). In our panel of cell 
lines, HDLM2, a Hodgkin lymphoma line, expressed the 
highest levels of full-length PD-L1 and secPD-L1 RNA 
compared to other PD-L1-expressing cell lines, SKBR3, 
MDA231, and Caki-2. This was expected since Hodgkin 
lymphomas express high levels of full-length PD-L1 protein 
often due to a genomic amplification of the 9p24 region 
that encodes PD-L1 gene [12]. Cell lines with undetectable 
levels of full-length PD-L1 by Western and flow cytometry 
also expressed extremely low levels of PD-L1 mRNA and 
secPD-L1 mRNA by quantitative RT-PCR. Of note, full-
length PD-L1 was expressed at 5–16fold higher levels than 
secPD-L1 within each cell line expressing full-length PD-L1 
tested in the representative experiment in Fig. 2c.
Transcriptomic analysis of the TCGA database found 
that secPD-L1 frequently is expressed in a subset of patients 
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across tumor types The difference between the 3′ ends of the 
full-length and secPD-L1 allows for computational analysis 
of mRNA expression levels of full-length and secPD-L1 in 
normal and tumor databases. We first verified our methods 
of analysis (Supplemental Fig. 2a) by screening tumor cell 
line transcriptomes in the Cancer Cell Line Encyclope-
dia (CCLE) that we had established as PD-L1-positive by 
protein analysis, such as HDLM2, SKBR3, MDA231, and 
Caki-2 or negative (such as BT474). Interrogation of TCGA 
showed secPD-L1 expression correlated with full-length 
PD-L1 expression (corr = 0.55, p < 2.2e-16, Fig. 3a). 70% 
of tumors in TCGA (6871/9677) expressed some amount of 
secPD-L1 compared to 98.6% that expressed some amount 
of full-length PD-L1 (Table 1). We found that the full-length 
PD-L1 was expressed at higher amounts and in more tumors 
than secPD-L1 transcripts across tumor types, a pattern sim-
ilar to that shown by qRT-PCR in cell lines (Fig. 2c). We 
divided each tumor type within TCGA into four categories 
based on whether they expressed secPD-L1 without full-
length PD-L1 (yellow), full-length PD-L1 without secPD-L1 
(blue), both full-length PD-L1 and secPD-L1 (green), or nei-
ther form of PD-L1 (grey) (Fig. 3b). The majority (median 
75.5%, range 25.7–97.0) of tumor types in TCGA express 
both splice forms (Fig. 3b, green). Only 0.9% of total tumors 
in TCGA expressed secPD-L1 without full-length PD-L1 
(Fig. 3b, yellow; Table 1). However, some tumor types had 
a small percentage that expressed only secPD-L1 (yellow, 
median 0%, range 0–3.8) with over 2% in liver hepatocellu-
lar carcinoma (LIHC), uterine corpus endometrial carcinoma 
(UCEC), uterine endometrial carcinoma (USC), and adren-
ocortical carcinoma (ACC), and acute myeloid leukemia 
(LAML). When we analyzed data from two small cohorts 
of previously reported patients with melanoma treated with 
immune checkpoint therapy [24, 25], we found nearly all 
melanoma specimens (98.5%) in both immune check point 
inhibitor-treated cohorts expressed some full-length PD-L1 
(ipilimumab n = 40, PD-1 blocker n = 28), which was com-
parable to that (98.9%) in the cohort of cutaneous melanoma 
specimens in the TCGA (Supplemental Fig. 2d–e). In the 
cohorts of patients treated with a CTLA-4 or PD-1 blocker 
the majority of melanomas did express secPD-L1 (60 and 
82%) and there was no association between clinical outcome 
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Fig. 2  SecPD-L1 is functional and is expressed in PD-L1 “positive” 
tumor cells. a Proliferation of CD3/CD28 activated T lymphocytes 
in the presence of recombinant secPD-L1, the soluble monomeric 
extracellular domain of PD-L1 (ECD-PD-L1) or an immunoglobulin-
HA tagged fusion protein as control after 72 h (*p value < 0.05, **p 
value < 0.005, ***p value < 0.0005). b IFN-γ production of CD3/
CD28-activated T lymphocytes after treatment as in a was assayed 
after 48  h. c Quantitative RT-PCR of full-length and secPD-L1 in 
tumor cell lines (lymphoma: HDLM2, OC1-LY1; kidney cancer: 
CAKI-2, UMRC6; and breast cancer: SKBR3, MDA231 and BT474)
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Transcriptomic analysis of the GTEx database found 
that secPD-L1 can be expressed in normal tissue To assess 
expression of secPD-L1 and full-length PD-L1 in normal 
tissues, we analyzed the GTEx database of RNASeq from 
specimens isolated from different human tissues (Fig. 2d). 
As seen in TCGA, the vast majority of normal tissue 
expressed some amount of full-length PD-L1 (green and 
blue). However, there were fewer normal tissue specimens 
with expression of secPD-L1 (green and yellow). Of note, 
the expression of secPD-L1 was highest in the lung, liver, 
and pituitary, but the minority of normal tissues express 
detectable levels of secPD-L1 by this analysis. Thus, while 
secPD-L1 is modestly expressed in many normal tissues, 
secPD-L1 expression appears to be increased in tumors 
when comparing TCGA with GTEx (Fig. 3b, c, green and 
yellow bars, median 75.6 and 27.3%).
secPD-L1 can be expressed by various hematologic cells, 
but is strongly associated with myeloid-derived suppressor 
cell-signatures in TCGA While the full-length PD-L1 protein 
is expressed in some normal tissues, such as placenta and 
the eye, its most established role is in hematologic cells, 
such as dendritic cells, macrophages, and activated lympho-
cytes. Since TCGA and GTEx databases are produced from 
bulk RNASeq of tissue specimens, they do not distinguish 
whether the cell type expressing the transcript is tumor cell, 
epithelial cell, stromal or immune cells. Others have shown 
that activated monocyte-derived dendritic cells produce 
soluble PD-L1 by cleavage from the membrane [15] and 
the RNASeq analysis indicates that a fraction of monocytes 
and classical dendritic cells express secPD-L1. Therefore, 
we confirmed that activated monocyte-derived dendritic 
cells express secPD-L1 mRNA, as well as full-length 
PD-L1 mRNA by qRT-PCR (data not shown). To determine 
which distinct hematologic cell types from healthy donors 
expressed secPD-L1 and full-length PD-L1, we analyzed the 
RNA expression of sorted peripheral blood cells (Fig. 3d). 
We found that neutrophils, as well as some subtypes of lym-
phoid and myeloid cells express secPD-L1 RNA.
Given that full-length PD-L1 is expressed in 98.6% of 
specimens in TCGA, while secPD-L1 is expressed in 70.5% 
of specimens, we performed differential expression analy-
sis depending on whether tumors expressed any secPD-L1. 
Differential expression analysis of samples with detectable 
secPD-L1 (n = 6821) or no-secPD-L1 (n = 2856) found 75 
genes and 234 genes with twofold or more increase in the 
secPD-L1 expressing and no-secPD-L1 cohorts, respec-
tively (Fig. 4a, FDR 5%). Full-length PD-L1 (CD274) was 
the most significantly associated gene with the secPD-L1 
expressing cohort, followed by IFN-γ and S100A8 (Fig. 4b). 
Compared to the no-secPD-L1 cohort, the secPD-L1 cohort 
expressed significantly higher levels of certain cytokines 
and chemokines, including IL21, CSF2, CCL25, and 
CCR9 (Supplemental Fig. 3a). Interestingly, Zlatko’s gene 
sets overlap analysis of sec-expressing and no-secPD-L1 
expressing TCGA cohorts showed that the myeloid-derived 
suppressor cell gene set was associated with the sec-express-
ing cohort, while the eosinophil gene set was associated with 
no-secPD-L1 expressing cohort (Fig. 4c).
Discussion
Tumor expression of PD-L1 inhibits the anti-tumor immune 
response and lets tumors evade immune attack [29, 30]. Tar-
geting PD-1 and its ligand PD-L1 has shown outstanding 
clinical benefit in clinical trials, and has significantly less 
toxicity than IL-2 or CTLA-4 blockade, leading to their 
FDA approval for numerous indications, including not only 
melanoma and non-small cell lung cancer, but also kidney 
and bladder cancer, as well as others including refractory 
Hodgkin’s lymphoma. For lung cancer patients with high 
PD-L1 expression on tumor cells (> 50%), starting treatment 
with the PD-1 blocking therapy pembrolizumab results in 
better survival than starting with chemotherapy [31]. How-
ever the role of PD-L1 as a biomarker has not proven to be 
sufficiently definitive to be clinically useful in most other 
settings. In tumors such as kidney cancer, PD-L1 expression 
on the tumor cells has been correlated with tumor aggres-
siveness and shorter patient survival, but this did not trans-
late into longer survival in “high” PD-L1-expressing kidney 
tumors when treatment with PD-1 blockade (nivolumab) was 
compared to everolimus in patients who had previously been 
treated with a VEGF tyrosine kinase inhibitor [4, 32]. While 
it is critical to determine what biomarkers are useful for 
predicting who will respond to PD-1 blockade alone and 
who will require combination therapy, surface expression 
of PD-L1 has not proven to be a simple or straightforward 
biomarker in most tumors at the protein or RNA level. A 
soluble form of PD-L1 also has been described and may be 
produced by multiple mechanisms, including cleavage from 
the surface of the cell [16] or alternate splicing [17]. This 
study is the first to assess the function of a secreted splice 
variant of PD-L1 that can dimerize and its expression in 
tumor and normal cells.
PD-L1 protein expression has been described both on 
tumor cells and on immune cells within the tumor microen-
vironment. Thus, stratifying PD-L1 expression of the tumor 
cell by RNA expression in bulk analysis of tumors is not 
feasible. For example in Hodgkin’s lymphoma, while PD-L1 
is highly expressed on Hodgkin Reed-Sternberg cells due to 
a chromosomal amplification of the PD-L1 gene, the bulk of 
the tumor mass is normal immune cells [12]. Furthermore 
different cell-surface PD-L1 mRNA variants can produce 
higher levels of protein expression on the tumor cells’ sur-
face, as shown by the effect of structural variations in the 
3′ UTR region of PD-L1 mRNA found in a small subset 
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of tumors [13]. In addition, expression of membrane-bound 
PD-L1 is regulated during the cell cycle by polyubiquitina-
tion of a lysine in the PD-L1 cytoplasmic domain; how-
ever, secPD-L1 lacks the cytoplasmic domain and therefore 
should be regulated in a different fashion. Most solid tumors’ 
PD-L1 expression is extremely variable and likely not driven 
by a single genetic driver mutation. Often the biomarker 
threshold of “positive” expression is relatively low at 1 or 
10% tumor cells.
Little is known about the normal biology of splice vari-
ants of PD-L1. However in many studies, membranous 
expression of PD-L1 on tumor cells is used to determine 
specific PD-L1 expression. Whether some of the non-spe-
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to splice variants without the transmembrane domain has not 
been determined. The calculated size of unmodified secPD-
L1 would be 26 KD but the observed 42 KD size in Fig. 1c is 
likely due to post-translational modifications such as glyco-
sylation. Not only does PD-L1 have four glycosylation sites 
in the extracellular domain shared by secPD-L1 and full-
length PD-L1, but the unique carboxyl terminus of secPD-
L1 also contains an N-linked glycosylation site. Our analy-
sis of TCGA shows that mRNA expression of full-length 
PD-L1 with a transmembrane domain was a log-fold greater 
than secPD-L1 expression (Supplemental 1C), suggesting 
full-length PD-L1 is the major form of PD-L1. In Genbank 
and as illustrated in Fig. 1, the full-length PD-L1 is variant 
1, the longest form (isoform a). Variant 2 (isoform b) is a 
shorter protein that lacks the IgV exon necessary for bind-
ing the PD-1 receptor. Variant 3 contains multiple in-frame 
stop codons which likely results in a non-coding RNA. The 
secPD-L1 mRNA is transcript variant 4 (NCBI Reference 
Sequence: NM_001314029.1). Recently we reported addi-
tional splice variants of PD-L1 in melanoma tumors, which 
have the PD-1 binding domain and cytoplasmic exons but 
do not include the transmembrane domain [17]. The most 
significant difference in the secPD-L1 variant from previ-
ously described splice variants is the carboxyl terminus of 
secPD-L1 and its capacity to dimerize. Despite analyzing 
multiple thresholds of positive secPD-L1 and full-length 
PD-L1 in the clinical cohorts that we had access to, we did 
not find that secPD-L1 expression predicted clinical out-
comes better than full-length PD-L1 expression. Therefore, 
in this study, we used a binary ± expression of secPD-L1 to 
present our transcriptomic analysis of secPD-L1 and full-
length PD-L1. Others have shown the 3′ UTR regions of 
full-length PD-L1 mRNA contains regulatory regions that 
control mRNA stability. The unique 3′ UTR of secPD-L1 is 
different and contains fewer AUUUA motifs than full-length 
PD-L1 mRNA and consequently may be a more stable tran-
script than the full-length PD-L1 mRNA. More extensive 
proteomic analysis of large cohorts may determine whether 
secPD-L1 protein is a better biomarker than full-length 
PD-L1 in the right context.
Whether soluble PD-L1 in the peripheral blood of cancer 
patients is a useful biomarker is not yet clear. Circulating 
levels of soluble PD-L1 have been correlated with worse 
clinical features and outcomes across tumor types, including 
RCC, multiple myeloma, and diffuse large B-cell lymphoma 
[5–9]. In melanoma, high serum levels of PD-L1 prior to 
treatment with immune checkpoint therapy also are associ-
ated with progressive disease [17]. However, soluble PD-L1 
in peripheral blood is not associated with worse prognosis 
in patients with pancreatic cancer; nor are soluble PD-L1 
levels associated with PD-L1 expression on pancreatic tumor 
cells; but soluble PD-L1 levels are associated with mark-
ers of inflammation, such as C-reactive protein (CRP) and 
strong infiltration of T cells into the tumor [33]. Here, we 
show that secPD-L1 can be expressed by tumor and normal 
cells. The composition of the pool of soluble PD-L1 found 
in the peripheral blood likely includes secPD-L1 and a mix-
ture of different variants of soluble PD-L1 cleaved from the 
surface and secreted alternative splice variants. Moreover, 
levels of soluble PD-L1 are elevated in pregnancy [34], and 
also in patients with pancreatitis associated with infectious 
complication [35], suggesting that elevated soluble PD-L1 
levels may be immunosuppressive at a distance even in non-
malignant settings.
Here we describe a secreted splice variant of PD-L1 
(secPD-L1) which is expressed in the majority of can-
cers, can dimerize and inhibit activation of T lymphocytes 
in vitro. This secreted splice variant of PD-L1 was indepen-
dently identified in a head and neck squamous cell carci-
noma with a human papilloma virus integration in the PDL1 
locus upstream of the transmembrane domain-encoding 
region, as described by Hassounah et al. in “Identification 
and characterization of an alternative cancer-derived PD-L1 
splice variant”, which is being copublished with our work. 
The integration of human papilloma virus upstream of the 
Fig. 3  SecPD-L1 RNA expression is associated with full-length 
PD-L1 expression and is found in the majority of human tumors 
and also some normal hematologic cells. a Correlation of secPD-L1 
expression with full-length PD-L1 RNA expression in The Cancer 
Genome Atlas (TCGA) data (normalized to total RNA transcripts, 
n = 9677 tumors, correlation = 0.55, p = 2.2e− 16). b Frequency of 
secPD-L1 and/or full-length PD-L1 within each tumor type in the 
TCGA. Each specimen was assigned to one of four classes: full-
length− sec+ (yellow shades), full-length + sec+ (green shades), 
full-length+ sec− (blue shades), full-length− sec− (grey) based on 
the frequency of the secPD-L1 and full-length PD-L1 isoforms (num-
ber of specimens per tumor type listed in parenthesis). The expres-
sion value of a sample within any class was color-shaded as follows. 
The interquartile range of the overall distribution of both isoforms 
was divided into 10 equal groups, with the first and last groups sub-
suming values ≤ 25th and ≥ 75th quartile, respectively. The expres-
sion of a sample within a class was represented by the appropriate 
color on the class-specific color gradient (color gradient created 
using colorRampPalette in R; full-length− sec+: yellow–yellow, full-
length + sec+: light green–dark green, full-length+ sec−: light blue–
blue, full-length− sec−: grey). The level of full-length PD-L1 counts 
is represented by the gradient of color of the full-length+ sec+ and 
full-length+ sec− groups; the level of secPD-L1 count is repre-
sented by the color yellow gradient in the full-length− sec+ group. 
c Frequency of secPD-L1 and/or full-length PD-L1 in normal tissue 
in GTEx (number of specimens per tissue type in parenthesis). The 
expression of the full-length+ sec+ and full-length+ sec− classes was 
represented by the normalized full-length PD-L1 count while the full-
length− sec+ group was represented by the corresponding normalized 
secPD-L1 count, with darker color representing higher expression 
of full-length PD-L1 or secPD-L1, respectively. d Some lympho-
cytes, myeloid cells and neutrophils expressing full-length PD-L1 
also express secPD-L1 (secPD-L1+ and full-length PD-L1+ in green, 
secPD-L1 negative and full-length PD-L1+ in blue, and secPD-L1 
negative and full-length PD-L1 negative in grey; transcripts normal-
ized to total transcripts)
◂
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transmembrane domain-encoding region favors the expres-
sion of the secreted form of PD-L1 and their analysis sub-
stantiates the expression of this secreted isoform of PD-L1 
across numerous cancers. Furthermore, we show that this 
isoform is expressed by PD-L1-positive tumor cells, and 
also PD-L1-positive normal tissue, including myeloid cells, 
such as dendritic cells. Since secPD-L1 is not exclusive to 
the tumor cells, it can be inferred that soluble PD-L1 in the 
peripheral blood may not be a simple surrogate for PD-L1 
expression by tumor cells. Moreover, the level of soluble 
PD-L1 is dynamic. After starting immune checkpoint ther-
apy, levels of soluble PD-L1 often rise, though within the 
first few months of treatment, this change is not associated 
with better outcomes [17]. Yet patients who survive beyond 
5 months and have higher serum PD-L1 levels were more 
likely to develop partial responses. We currently do not have 
a means to distinguish different protein forms of soluble 
PD-L1. Soluble PD-L1 found in serum may be produced by 
multiple cell types and through different mechanisms, such 
as cleavage from the cell surface by a matrix metalloprotease 
[16] or alternative expression of PD-L1 splice variants. Our 
data indicate that a monomeric form of soluble PD-L1 is less 
effective at inhibiting T-cell activation than secPD-L1. The 
biological activity of secPD-L1 required relatively high con-
centrations in vitro, suggesting that secPD-L1 might be most 
active in the tumor microenvironment rather than systemi-
cally, since the concentration of soluble PD-L1 in the periph-
eral blood of patients rarely reaches 10 µg/ml [5–9]. Since 
its inhibitory effect does not depend on a cell-to-cell interac-
tion, it may be a novel mechanism of mediating immunosu-
pression within the tumor microenvironment in a paracrine 
manner. The differences in immunologic gene expression in 
the sec-expressor cohort and no-secPD-L1-expresser cohort 
in TCGA illustrate that multiple immunologic pathways are 
active in the secPD-L1 expressing tumors. Further under-
standing the tumor biology of PD-L1 and its splice variants 
will improve our means of overcoming resistance to PD-L1/
PD-1 pathway therapy.
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